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A B S T R A C T
Despite life-style advice and the prescription of cholesterol-lowering and anti-thrombotic drugs, cardiovascular
diseases are still the leading cause of death worldwide. Therefore, there is an urgent need for new therapeutic
strategies focussing on atherosclerosis, the major underlying pathology of cardiovascular diseases characterized
by an accumulation of lipids in an inflamed arterial/vessel wall. CD1d-restricted lipid-sensing natural killer T
(NKT) cells, bridging the innate and adaptive immunity, and CD1d-expressing antigen-presenting cells are
detected in atherosclerotic lesions of mice and humans. In this review we will summarize studies that point to a
critical role for NKT cells in the pathogenesis of atherosclerosis and other cardiovascular diseases by the
secretion of pro-atherogenic cytokines and cytotoxins. These pro-atherogenic NKT cells are potential targets for
new therapeutic strategies in the prevention and treatment of cardiovascular diseases. Additionally, proteins
transferring lipids during atherosclerosis, which are also important in the loading of lipids onto CD1d and
possible endogenous ligands responsible for the activation of NKT cells during atherosclerosis will be discussed.
1. Introduction
It is well established that both innate and adaptive immunity play a
significant role in cardiovascular diseases, including the development and
progression of atherosclerosis which was traditionally seen as a lipid-
disorder (Hansson, 2001). The immune responses are mainly triggered by
the accumulation and modification of low-density lipoproteins (LDL) in
the vessel wall. LDL particles, rich in cholesterol, get oxidized or glycated,
aggregate, associate with proteoglycans or are incorporated into immune
complexes (Khoo et al., 1992, 1988) resulting in immunogenic particles.
Macrophages take up the modified and especially oxidized LDL (oxLDL)
via scavenger receptors leading to the formation of lipid-loaded foam cells
and the secretion of cytokines and chemokines. This is one of the key-
processes in the development of atherosclerosis (Han et al., 1997; Khoo
et al., 1992). Subsequently, immunogenic peptide and lipid antigens,
especially derived from modified auto-antigens such as oxLDL and heat
shock proteins (i.e. HSP-60/65), are presented by surface CD1 (lipid
antigens) or major histocompatibility complex (MHC) class I and II
molecules (peptide antigens) on macrophages, dendritic cells (DCs) and B
cells. This initiates the activation of adaptive immune cells, primarily
CD4+ T cells including oxLDL-specific (Hansson et al., 1989; Stemme
et al., 1995) and HSP60/65-specific T cells (Afek et al., 2000; Benagiano
et al., 2005). Upon recognition of the peptides the naïve T cells turn into
effector (memory) T cells, especially Th1 effector cells, producing the pro-
atherogenic cytokine IFN-γ. The local production of cytokines and
chemokines by inflammatory cells, leads to a continuous influx of
inflammatory cells into the vessel wall and together with an ineffective
clearing of dead cells (efferocytosis) this results in a chronic inflammatory
process, progressing atherosclerotic lesion development.
Since lipids are very important in the development of atherosclerosis,
the discovery of lipid-sensing T cells, the natural killer T (NKT) cells, led to
an intensive investigation on the possible role of these cells in cardiovas-
cular diseases and especially in atherosclerosis. Here we review the role and
function of NKT cells in cardiovascular diseases with a special focus on
atherosclerosis and the possibilities to target or modulate these cells as a
therapeutic strategy in the prevention of cardiovascular diseases.
2. NKT cells
NKT cells represent a distinct subset of T cells expressing unique TCRs
and surface markers commonly expressed by NK cells including NK1.1,
Ly49, CD16 and CD122. The unique TCRs of NKT cells are restricted to
certain (glyco)lipid antigens while conventional T cells show a wide
diversity of TCRs directed against numerous peptide antigens. The
(glyco)lipids are presented to the NKT cells on the MHC class I like
molecule CD1d in association with β2-microglobulin. CD1d, highly con-
served in mammalian species, is constitutively expressed on antigen-
presenting cells (APCs) such as macrophages, DCs and B cells. In addition,
CD1d is also expressed by other cells including thymocytes necessary for
the development of NKT cells (Gapin et al., 2001), hepatocytes (Agrati et al.,
2005), intestinal Paneth cells (Monzon-Casanova et al., 2010) and vascular
smooth muscle cells (VSMCs) (Canchis et al., 1993). The CD1d-restricted
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NKT cells can be subdivided into two types. Type I NKT cells, also referred
to as invariant (i)NKT cells are the most common ones in mice expressing a
semi-invariant T cell receptor (TCR) composed of a Vα14-Jα18 (formerly
Vα14-Jα281) TCRα chain paired with a Vβ2, Vβ7 or Vβ8.2 TCRβ chain,
while in humans this TCR is composed of a Vα24Jα18 TCRα chain and a
Vβ11 TCRβ chain. Type II NKT cells, the most common NKT cell type in
humans but less frequent in mice, do not express these invariant TCRs but
have more variable TCRs. In mice type I NKT cells can again be subdivided
into two subsets distinguishable by the expression of CD4 and CD8:
CD4+CD8- NKT cells and CD4/CD8 double negative (DN) NKT cells.
Humans have an additional subset of CD4-CD8+ NKT cells. Type I and
Type II NKT cells can also be distinguished based upon lipid recognition.
Type I NKT cells are potently activated by α-galactosylceramide (α-GalCer),
while type II NKT cells respond to the self-glycolipid sulfatide, present in
several membranes throughout the body (Arrenberg et al., 2010; Jahng
et al., 2004). In mice, NKT cells are most frequently found in the liver (10–
35% of liver lymphocyte population) and less frequent (0.2–2.5% of
lymphocytes) in spleen, thymus, lymph nodes, bone marrow and blood.
In humans, the percentage of NKT cells within the lymphocyte population
throughout the body is much lower ranging from 0.3% to 1%.
NKT cells can get activated via different pathways including CD1d/
TCR-dependent pathways, discussed in more detail in Sections 4–6,
but also CD1d/TCR-independent pathways such as cytokine-driven
activation. Cytokines, such as IL-12 and IL-18, produced by pathogen-
activated APCs during for example infections with Salmonella typhi-
murium, Staphylococcus aureus and Mycobacterium tuberculosis can
activate the NKT cells via the IL-12R and IL-18R expressed on their
surface (Eberl and MacDonald, 1998; Leite-De-Moraes et al., 1999).
More recent studies have shown that IL-33 in cooperation with IL-12
can activate and stimulate IFN-γ production by NKT cells (Bourgeois
et al., 2009). In general it is a combination of both CD1d-dependent
and CD1d-independent pathways leading to the activation of NKT cells.
Although NKT cells might have a lower threshold for activation than
conventional T cells, co-stimulatory pathways such as CD28/B7, ICOS/
ICOSL, CD40L/CD40, and OX40/OX40L and co-inhibitory pathways
such as PD1/PD-L also influence the activation status of NKT cells.
Upon stimulation, all NKT cells react rapidly by secreting robust
amounts of a variety of pro-inflammatory Th1 cytokines (IFN-γ, IL-12,
TNF-α, IL-2, IL-6) and anti-inflammatory Th2 cytokines (IL-4, IL-5,
IL-10, IL-13). Additionally, NKT cells rapidly acquire cytolitic activity
which results in the secretion of granzyme B, perforin, or FasL. This
makes NKT cells a unique cell type bridging the adaptive and the innate
immune system. Activation of NKT cells also leads to a robust
bystander activation of a wide variety of other inflammatory cells such
as dendritic cells (Fujii et al., 2003; Kitamura et al., 1999), monocytes
(Hegde et al., 2009), macrophages (Villanueva et al., 2015), NK cells
(Carnaud et al., 1999), B cells (Kitamura et al., 2000) and T cells (Eberl
et al., 2000; Nishimura et al., 2000).
Numerous studies have shown that dysfunctional NKT cells or
reduced numbers of NKT cells in humans and mice can be linked to
several diseases varying from cancer (Tahir et al., 2001) to infectious
(Kee et al., 2012; Mureithi et al., 2011) and autoimmune diseases (Kis
et al., 2007; van der Vliet et al., 2001; Yanagihara et al., 1999). This is
confirmed by a bunch of studies with mouse models showing that an
adoptive transfer of NKT cells or glycolipid-induced activation of NKT
cells (mostly α-GalCer, discussed in Sections 4 and 5) leads to a
protection against diabetes (Hong et al., 2001), experimental auto-
immune encephalomyelitis (Jahng et al., 2001), colitis (Saubermann
et al., 2000), arthritis (Coppieters et al., 2007) and several types of
cancer (Van Kaer et al., 2011).
3. NKT cells in atherosclerosis
3.1. CD1d-expressing cells and NKT cells in atherosclerotic lesions
The first study on a possible role of NKT cells in atherosclerosis
emerged in 2002. In this study apoE-/- mice were treated with LPS and
showed increased plaque size correlating with increased numbers of IL-
4 producing NKT cells. It was suggested that these NKT cells might be
responsible for the increased levels of autoantibodies against oxLDL
leading to the increase in atherosclerotic lesion development (Ostos
et al., 2002). Bobryshev et al. and Melián et al. were the first to detect
the expression of CD1d on respectively DCs and macrophages in
human atherosclerotic lesions (Bobryshev and Lord, 2002; Meliá
et al., 1999). Later on, NKT cells were detected in human athero-
sclerotic lesions isolated from aneurysm patients. NKT cells expressing
the IL-18 receptor predominated over NKT cells expressing ST2L and it
was suggested that the IL-18R and ST2L expression on NKT cells might
be an important determinant of the immune status in atherosclerosis
(Chan et al., 2003). Bobryshev et al. established that NKT cells, present
in human carotid arteries with advanced atherosclerotic lesions co-
localize with CD1d expressing DCs in the plaque shoulders of the
lesion. The direct interaction between these cells confirmed that NKT
cell activation occurs inside the lesion and may contribute to plaque
instability (Bobryshev and Lord, 2005).
3.2. CD1d deficiency and atherosclerosis
These studies were the beginning of an increased interest in the
possible role of NKT cells during hyperlipidaemia and atherosclerosis,
especially because of the lipid-sensing capacity of these cells and their
association with decreasing the inflammatory response. However,
atherosclerotic lesion formation at the aortic root was found to be
reduced in CD1d-/- mice, lacking type I and II NKT cells, when
compared with wild-type (C57Bl6) mice and in CD1d-/-→LDLr-/-
chimeras when compared with WT→LDLr-/- chimeras all fed a high-
fat diet containing fat, cholesterol and cholic acid (Nakai et al., 2004).
Subsequently, ApoE-/- and LDLr-/- mice were backcrossed with CD1d-/-
mice to generate hyperlipidemic mice lacking functional type I and type
II NKT cells. The deficiency in CD1d led to a reduced atherosclerotic
lesion size in both the aortic root and throughout the whole aorta of
mice fed a regular chow diet (Major et al., 2004; Tupin et al., 2004) or a
Western type diet (Aslanian et al., 2005), showing that NKT cells have a
pro-atherogenic function. The effects on lesion size were especially seen
during the initial stage of atherosclerosis characterized by mild
hypercholesterolemia and fatty streak formation which is consistent
with the suggestion that NKT cells mediate early immune responses at
inflammatory sites before the conventional T cells are activated.
Additionally, Ström et al. showed a reduced intima thickening in the
carotids of CD1d-/- mice upon vascular injury induced by a perivascular
collar around the carotid arteries under normocholesterolemic condi-
tions (Ström et al., 2007).
3.3. NKT cell subsets and atherosclerosis
To determine whether type I Vα14+ iNKT cells are important in
early atherosclerosis, LDLr-/-Jα281-/- mice which lack iNKT cells were
generated and fed a high fat diet. Compared with LDLr-/- mice
atherosclerotic lesion size was again reduced, establishing the profound
role of iNKT cells in atherosclerosis. In addition, LDLr-/-Jα281-/- mice
showed reduced splenocyte-secreted and lesion-associated IFN-γ con-
centrations providing strong evidence that the iNKT cells promote
atherosclerosis by producing IFN-γ themselves or by stimulating the
secretion of IFN-γ by other cells (Rogers et al., 2008). In accordance,
VanderLaan et al. showed that a transfer of splenocytes enriched with
type I Vα14+ iNKT cells (Vα14tg) to RAG1-/-LDLr-/- mice increased
atherosclerotic lesion size, and Subramanian et al. showed a similar
increase in lesion size in LDLr-/- mice crossed with Vα14tg mice. Both
studies demonstrate that the activation of the pro-atherogenic iNKT
cells relies on endogenous ligands, since no exogenous NKT cell
antigens are administered (Subramanian et al., 2013; VanderLaan
et al., 2007). A comparative study including both LDLr-/-Jα281-/- mice
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and LDLr-/-CD1d-/- mice fed the same high fat diet should now be
performed to give more insight in a possible contribution of other types
of CD1d-dependent NKT cells i.e. type II NKT cells.
In a more advanced approach to determine the contribution of
different subtypes of NKT cells to atherosclerosis, an adoptive transfer
of NKT cells to apoE-/- mice depleted of NKT cells by thymectomy
showed that CD4+ NKT cells but not DN (CD4-CD8-) NKT cells
augment the development of atherosclerosis (To et al., 2009). Similar
to the study by VanderLaan et al. (2007) this study suggests that NKT
cells are activated in vivo by endogenous ligands since no exogenous
ligands were administered to the thymectomized mice. The difference
in the pro-atherogenic capacity of both subtypes is associated with the
differential expression of Ly49, an inhibitory receptor which can be
activated by MHC class I molecules. Ly49 is more abundantly
expressed on the DN NKT cells and the high expression of MHC class
I in atherosclerotic lesions may therefore lead to a less pronounced role
of these highly pro-inflammatory cells in atherosclerosis. Although a
transfer of DN NKT cells did not have an effect on lesion size, they
exhibited an equal ability as CD4+ NKT cells to reduce the collagen
content of atherosclerotic lesions which proves that these effects are
independent of Ly49 and inflammatory cytokines such as IFN-γ (To
et al., 2009). The effect of NKT cells on collagen content of lesions,
already shown by Nakai et al. (2004) establishes the differential effects
of NKT cells in different stages of atherosclerosis. Although CD1d+ cells
are found more frequently in advanced atherosclerotic lesions than in
early lesions (Kyriakakis et al., 2010), no differences in lesion size were
observed upon NKT cell deficiency in more advanced stages of
atherosclerosis in mice (Aslanian et al., 2005). However, NKT cells
might still play a role in these more advanced stages by affecting the
collagen content and subsequently the lesion stability.
3.4. How NKT cells contribute to atherosclerotic lesion development
Until 2014, it was unknown how NKT cells exactly contribute to the
development of atherosclerotic lesions. As shown in Fig. 1, this could
either be via the increased secretion of pro-inflammatory and pro-
atherogenic cytokines by NKT cells or bystander activated leukocytes,
or by the induction of apoptosis via the cytotoxins of NKT cells,
granzyme B, perforin and FasL. Li et al. (2015) showed that adoptive
transfer of liver NKT cells into T- and B-cell deficient apoE-/-Rag2-/-
mice and T-, B- and NK cell deficient apoE-/-Rag2-/-γc-/- mice still
augmented atherosclerotic lesion development indicating that neither
T and B cells nor NK cells are necessary for NKT cells to affect the
development of atherosclerosis. These results disprove the study by
Andoh et al. in which they suggested that LPS-induced NKT cell
activation leads to an increase in and activation of NK cells, possibly
induced by NKT cell derived IFN-γ, and that these NK cells further
promote atherosclerotic lesion development (Andoh et al., 2013). This
link between NKT and NK cells can still be important, but is not
requisite for the contribution of NKT cells to lesion development.
Although it is obvious that cytokines, especially IFN-γ, produced by
NKT cells influence the development of atherosclerotic lesions, Li et al.
showed that CD4+ NKT cells can affect lesion development in a
cytokine-independent way, since IFN-γ-/-, IL-4-/- and IL-21-/- CD4+
NKT cells were still able to increase atherosclerotic lesion size after
adoptive transfer. This conclusion might be a bit premature since Ito
et al. suggested that NKT cells might be pro-atherogenic via the
production of TNF-α induced by the bioactive lipid sphingosine-1-
phosphate (S1P). Therefore, an adoptive transfer of TNF-α deficient
NKT cells should be performed (Ito et al., 2014). However, adoptive
transfer of CD4+ NKT cells deficient in granzyme B or perforin failed to
increase atherosclerotic lesion size indicating that both perforin and
granzyme B are required for the pro-atherogenic action of CD4+ NKT
cells. Granzyme B and perforin, known for their pro-atherosclerotic
effects (Choy et al., 2003; Hiebert et al., 2013; Kyaw et al., 2013),
induce apoptosis in a caspase-3 dependent way and subsequently
augment post-apoptotic necrosis, appreciated by an increased necrotic
core size within the lesions (Li et al., 2015). CD1d-expressing cells are
specifically targeted by NKT cells for killing via the Granzyme-B/
perforin mechanism (Gansuvd et al., 2002; Metelitsa et al., 2003)
which means that especially CD1d expressing DCs, macrophages and
thus foam cells are targets for these cells leading to more vulnerable,
rupture-prone lesions with excessive apoptosis and large necrotic
cores.
3.5. Prevalence of NKT cells during atherosclerosis
Studies on the prevalence of NKT cells in different organs during
atherosclerosis show contradictory results. Some studies found de-
creased NKT cell numbers in liver and spleen of apoE-/- mice upon age
(Major et al., 2004) or upon high fat diet feeding (Nakai et al., 2004)
suggesting a decline in NKT cells upon the progression of athero-
sclerosis which is in line with the findings in many other autoimmune
disorders (Kis et al., 2007; van der Vliet et al., 2001; Yanagihara et al.,
1999). Although less frequent, the remaining NKT cells produce
relatively more cytokines. The reason for the decrease in NKT cell
numbers remains however elusive. Increased cell death, a down-
regulation of NK1.1 and the TCR or an increased migration to
peripheral tissues might be responsible for the lowering in NKT cell
numbers. Since NKT cells express a broad range of chemokine
receptors similar to Th1 cells such as CCR4, CCR5, CCR6, CXCR3,
CXCR4 and CXCR6 (Thomas et al., 2003), it is very well possible that
NKT cells are activated elsewhere in the body (liver/spleen) and then
migrate to the atherosclerotic lesions upon chemokine release inside
the lesions including CCL2, CCL3, CCL4, CCL5, CXCL10, CXCL12 and
CXCL16, leading to the reduced NKT cell numbers in the peripheral
organs. Aslanian et al. observed that NKT cells are already present in
aortic arches of chow fed LDLr-/- mice but not in LDLr+/+ mice.
Feeding the LDLr-/- mice a high fat diet did not further increase the
number of NKT cells which shows that a slight increase in serum
cholesterol may already be adequate to induce the secretion of NKT cell
recruiting chemokines (Aslanian et al., 2005). Similar to this study,
Rombouts et al. (2016) detected Vα14-Jα18 mRNA in early lesions but
no accumulation of Vα14-Jα18 in more advanced lesions. Further
research is needed to confirm that an increased recruitment is
responsible for the decline in peripheral NKT cells, especially because
of the high numbers of NKT cells in the liver and spleen, and the
relatively low numbers inside the lesions. On the other hand we and
others found an increase in the number of NKT cells upon high fat diet
feeding. NKT cell infiltration was enhanced in adipose tissue of mice on
a high fat diet (Ohmura et al., 2009) and we observed an extensive
increase in CD3+NK1.1+ NKT cell percentages in liver and spleen of
LDLr-/- mice, but not in apoE/- mice both fed a high fat diet for 1.5
weeks (van Puijvelde et al., 2009).
4. Modulation of NKT cells responses during atherosclerosis
4.1. Pro-atherogenic effects of α-GalCer
As mentioned before, a glycolipid-induced activation of NKT cells
leads to a protection against several autoimmune diseases. Therefore,
glycolipid-induced activation of NKT cells had the potential for a
possible therapy in atherosclerosis. α-GalCer is known as the most
potent activator of iNKT cells and was discovered by Kirin Brewery Co.,
Ltd., during their search for natural anticancer medicines (Kawano
et al., 1997). α-GalCer, a natural product found in the marine sponge
Agelas mauritianus and now linked to Sphingomonas, bacteria which
are present in the sponge, is now chemically synthesized and also
known as KRN7000 (Morita et al., 1995). Especially when injected
multiple times, α-GalCer has shown a great potential to dampen a wide
range of immune responses in mouse models including several chronic
autoimmune diseases, but also affects antitumor responses, defence
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against pathogens and allergy. However, in line with the findings in
NKT cell deficient mouse models, several studies with different
administration regimens of α-GalCer to apoE-/- mice (three times in
total to twice weekly over a period of 5–11 weeks) led to a CD1d-
dependent increase in early atherosclerosis at the aortic root without
affecting cholesterol and triglyceride levels (Nakai et al., 2004; Tupin
et al., 2004). The increase in atherosclerotic lesion size after α-GalCer
administration is attributed to a burst of cytokines (IFN-γ, TNF-α, IL-
2, IL-4, IL-5, and IL-10) in the serum. Initially the NKT cell numbers in
the spleen and liver drop, shifting to an increase in the spleen and the
aorta after 3 days (Tupin et al., 2004). The initial drop in NKT cells
might be caused by an increased recruitment of NKT cells from the
spleen and liver to the atherosclerotic lesions where they become
activated and secrete IFN-γ and IL-4. Subsequently, a bystander
activation of macrophages and endothelial cells in the lesion might
occur since an increased VCAM-1 and I-Ab expression in the lesions
was observed (Tupin et al., 2004). In line with the studies with NKT cell
deficient mice, α-GalCer treatment of mice with more advanced
atherosclerotic lesions at the aortic root did not affect lesion size but
increased the instability of lesions, characterized by a lower collagen
content and an increased cellularity (Nakai et al., 2004).
4.2. α-GalCer as anti-atherogenic factor
Immediately after a single injection of α-GalCer, NKT cells secrete
large amounts of pro-inflammatory cytokines (Th1 profile) as shown in
both naïve mice (Tupin et al., 2004) and mice with established
atherosclerotic lesions (Major et al., 2004). Repeated injections of α-
GalCer led to undetectable levels of the cytokines in the serum although
spleen mRNA expression analysis still showed increased levels of IFN-γ
and IL-4 (Tupin et al., 2004). On a longer term (i.e. 2 weeks after the
administration), multiple injections of α-GalCer lead to a Th2 cytokine
profile of NKT cells in which increased levels of IL-4 and IL-10 were
detected with only a slight increase in IFN-γ levels (Major et al., 2004).
In line with this cytokine profile, but in contrast with the other studies
which suggest a pro-atherogenic effect of α-GalCer treatment, we found
that a mixed intravenous (i.v.) and intraperitoneal (i.p.) administration
of α-GalCer increased the production of IL-4 and especially IL-10 in
the spleen and lymph nodes. These anti-inflammatory cytokines
contributed to a reduced thickening of the intima in carotid arteries
of LDLr-/- mice, but not apoE-/- mice using a perivascular collar model
which, in combination with hypercholesterolemia (9 weeks of high fat
diet), induces atherosclerotic lesion development in the carotid arteries
Fig. 1. How NKT cells can contribute to the development of atherosclerotic lesions. Accumulation and the subsequent modification (oxidation of LDL) of lipids in the vessel wall initiate
both adaptive and innate immune responses. Macrophages take up the oxidized LDL particles and turn into lipid loaded foam cells producing cytokines and chemokines which cause the
attraction of other leukocytes into the newly formed intimal layer of the vessel wall. Among these leukocytes are NKT cells which are found in close proximity of macrophages and
dendritic cells that express the antigen presenting molecule CD1d. Lipids presented on CD1d may be of endogenous or exogenous origin and are recognized by the T cell receptor of the
NKT cells. Although there are some possible candidates the lipid causing the activation of NKT cells during atherosclerosis is still unknown. The lipid-dependent activation of NKT cells
in the atherosclerotic lesion might result in the secretion of both pro-atherogenic cytokines (IFN-γ, IL-12, IL-6, IL-21, IL-2, TNF-α and IL-4) and anti-atherogenic cytokines (IL-10, IL-4,
IL-5 and IL-13). Pro-atherogenic cytokines, which are more abundantly produced than the anti-atherogenic cytokines, may cause (bystander) activation and expansion of other
leukocytes such as Th1 cells, B cells, NK cells and macrophages all stimulating plaque growth. Anti-atherogenic cytokines might on their turn prevent this by inhibiting macrophages and
T cell responses or by reducing the formation of necrotic cores. Lipid-independent activation of NKT cells, for example by cytokines released by Toll-like receptor 4 activated dendritic
cells, might lead to the release of granzyme B and perforin which results in a caspase-3 dependent killing of CD1d expressing cells (macrophages and dendritic cells). This process
contributes to the necrotic core formation and leads to bigger and especially more vulnerable lesions.
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(van Puijvelde et al., 2009). The most striking difference with other
studies on α-GalCer and atherosclerosis might be that we examined the
effects of α-GalCer in LDLr-/- mice, while other studies only used
apoE-/- mice. Both apoE and the LDLr are important mediators of lipid
transport and mediate in the presentation of lipids on CD1d and mice
deficient in these lipid-transfer related molecules might therefore have
a differentially disturbed behaviour of NKT cells leading to differences
in the responsiveness to α-GalCer (Elzen et al., 2005). In addition, as
mentioned in a study by Braun et al. the iNKT cells in hyperlipidemic
mice might be anergic due to a chronic activation by endogenous
ligands (Braun et al., 2010). Differences in lipid levels and thus in the
anergic state between apoE-/- mice and LDLr-/- mice might also explain
the different outcomes between both models upon treatment with α-
GalCer.
4.3. OCH
Even more unexpected were the effects of a treatment with
(2S,3S,4R)−1-O- (α-D-Galactopyranosyl)-N-tetracosanoyl-2-amino-
1,3,4-nonanetriol (OCH), a truncated analogue of α-GalCer, known
for the induction of a Th2-cytokine profile by NKT cells (Bricard et al.,
2010). While administration of OCH led to an anti-inflammatory
cytokine-dependent protection against arthritis (Chiba et al., 2004),
colitis (Ueno et al., 2005), insulitis and diabetes (Mizuno et al., 2004),
OCH-treatment of apoE-/- mice led to an increase in atherosclerotic
lesion size at the aortic root when compared with a vehicle control, but
the lesions were smaller than in α-GalCer-treated mice (Nakai et al.,
2004). Both ligands induced a similar IL-4 production, but α-GalCer
induced more IFN-γ. However, we now showed that treatment of
LDLr-/- mice with OCH-pulsed DCs strongly reduced the development
of atherosclerotic lesions due to increased levels of IL-10 and a
lowering in cholesterol (Puijvelde et al., submitted for publication).
4.4. DPPE-PEG
More recently, and in line with the study on the role of NKT cell
derived Granzyme B and perforin in necrotic core formation during
atherosclerosis (Li et al., 2015), Li et al. showed that treatment of
apoE-/- mice with 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N[methoxy (polyethyleneglycol)−350 (DPPE-PEG350) effectively re-
duced necrotic core size during both the development and progression
of hyperlipidaemia-induced atherosclerosis (Li et al., 2016). DPPE-
PEG is a lipid antagonist and inhibits the activation of iNKT cells by
preventing the presentation of activating ligands on CD1d (Lombardi
et al., 2010). Blocking the NKT cell activity by DPPE-PEG350 con-
comitantly reduced the attraction of CD4+ T cells, CD8+ T cells and B
cells to the lesion, suggesting an important role of activated NKT cells
in the recruitment of other inflammatory cells into the lesion. They now
suggest that the reduction in necrosis upon DPPE-PEG350 treatment
also leads to lower levels of damage-associated molecular patterns such
as the pro-atherogenic high mobility group box 1 (HMGB1) (Kanellakis
et al., 2011). Conclusively, DPPE-PEG350 is an interesting candidate to
target iNKT cells in pathologies in which NKT cells worsen the disease
such as cardiovascular diseases and atherosclerosis in particular (Li
et al., 2016).
5. Lipid-induced NKT cell activation
5.1. α-GalCer and analogues
Since NKT cells are involved in the development of atherosclerotic
lesions, the question raised which (modified) endogenous ligand might
be responsible for the systemic and local activation of the NKT cells. A
lot of research has been done on the glycolipids which are presented on
CD1d. These glycolipids mainly consist out of two major parts attached
to each other via a glycosidic bond: a lipid part which binds to the
hydrophobic binding site within the binding pocket of CD1d and a
hydrophilic carbohydrate head group which is exposed for recognition
by TCRs. Several studies have now shown that minor modifications to
the α-GalCer structure are well tolerated and still give NKT cell
activating ligands, however with differences in the cytokine-release
profile. While α-GalCer induces a mixed Th1 and Th2 cytokine
secretion, a small modification in the glycosidic bond leading to α-C-
GalCer, induces especially secretion of Th1 cytokines (IFN-γ) while a
truncated analogue of α-GalCer, OCH, as mentioned before preferen-
tially stimulates the secretion of Th2 cytokines (IL-4 and IL-10). These
variations in cytokine profile are presumably the consequence of
differences in the stability of CD1d-glycolipid complexes. A more
stabilized CD1d-glycolipid complex is formed with α-C-GalCer than
with OCH and since IFN-γ production requires a more prolonged TCR
stimulation than IL-4 and IL-10, binding of α-C-GalCer resulted in the
selective production of IFN-γ, while OCH biased the production of IL-4
and IL-10 (Miyamoto et al., 2001; Oki et al., 2004; Yang et al., 2004).
5.2. β-linked glycolipids
Although α-anomeric glycolipids such as α-GalCer are potent
agonists of murine and human iNKT cells, it was generally assumed
that it is unlikely that they are the endogenous ligands for NKT cells,
since these glycolipids are rarely found in humans and other mamma-
lian species (Tsuji, 2006). Extensive research has led to the identifica-
tion of two β-linked glycolipids, lysosomal isoglobotrihexosylceramide
(iGb3) (Zhou et al., 2004b) and disialoganglioside GD3 (Wu et al.,
2003) able to activate human and mammalian iNKT cells ligands and
both linked to atherosclerosis. GD3 is induced in atherosclerotic tissues
and in the circulation of apoE-/- mice (Garner et al., 2002; Mukhin
et al., 1995) while intermediates of the synthesis of iGb3, β-GlcCer and
lactosylceramide accumulate in the human atherosclerotic lesions
(Mukhin et al., 1995). It is still under debate whether these ligands
are indeed the endogenous agonist for NKT cells. More recent studies
have now shown that, despite the assumption that they cannot produce
α-anomeric glycolipids, mammalian immune cells produce constitu-
tively low amounts of α-glycosylceramides, controlled by catabolic
enzymes of the ceramide and glycolipid pathways (Kain et al., 2014). So
it remains elusive which glycolipid is the endogenous ligand for NKT
cells, especially during atherosclerosis.
5.3. Bacteria-derived glycolipids
The majority of the identified iNKT cell ligands are bacteria-derived
lipids. Microbial lipids, such as glycosphingolipid-1 (GSL-1) derived
from Sphingomonas (Long et al., 2007) and Ehrlichia muris (Mattner
et al., 2005), α-galactosyldiacylglycerol derived from Borrelia burg-
dorferi (Kinjo et al., 2006) and cholesteryl α-glucoside from
Helicobacter pylori (Chang et al., 2011) have been shown to be
recognized by iNKT cells. During bacterial infections, NKT cells play
a protective role in the host defence by actively contributing to the
clearance of the pathogens by different mechanisms. NKT cells might
be activated directly by recognition of the above mentioned glycolipid
antigens upon which they secrete cytokines, presumably IFN-γ, which
stimulates macrophages to secrete cytokines and actively phagocytose
the pathogens, or indirectly via LPS in which endogenous NKT cell
ligands and cytokines are involved (De Libero et al., 2005; Mattner
et al., 2005). LPS might inhibit an enzyme which normally degrades
iGb3, α-galactosidase A, thereby elevating iGb3 levels, and TLR
signalling leads to increased levels of the endogenous ligand β-
GlcCer, both leading to enhanced iNKT cell activation (Brennan
et al., 2011; Darmoise et al., 2010).
5.4. Phospholipids
Phospholipids are another important class of lipids with reported
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NKT cell stimulating capacity. The polar phosphate group of these NKT
cell activating ligands are generally linked to either an inositol group,
phosphatidylinositol (PI) such as phosphatidylinositol tetramannosides
(PIM4) fromMycobacterium bovis (Zajonc et al., 2006), or to a choline
(-like) group as seen in phosphatidylcholine (PC) (Giabbai et al., 2005)
and phosphatidylethanolamine (PE) (Joyce et al., 1998). Phospholipids
and oxidized derivatives are essential constituents of LDL and oxLDL
respectively. Upon exposure to oxLDL and lysophosphatidic acid,
macrophages and DCs increase the expression of CD1d in a peroxisome
proliferator activated receptor (PPAR)γ-mediated way (Leslie et al.,
2008; Szatmari et al., 2006). Together with an upregulation of TLR4
this subsequently enhances the activation of NKT cells resulting in
increased production of IFN-γ. These findings are important in the
context of atherosclerosis since lipids are abundantly present in the
lesions and NKT cells exacerbate atherosclerosis in LPS-treated mice
(Andoh et al., 2013; Nakai et al., 2004). VanderLaan et al. showed that
LDL present in serum of LDLr-/- mice on a high fat diet contains an
“endogenous” antigen able to stimulate Vα14Jα18-expressing hybri-
doma cells (NKT hybridoma). Loading of the antigens onto CD1d is
dependent on endocytosis facilitated by the LDL receptor. However,
upon extensive oxidation of LDL the endocytosis via the LDL receptor
is impaired, impairing the NKT cell stimulating capacity of LDL
(VanderLaan et al., 2007). The precise nature of the NKT cell activating
endogenous lipid in LDL remained however elusive since LDL is a
complex particle able to transport a wide range of lipids including
phospholipids. Fox et al. now showed that lysophosphatidylcholine, a
major phospholipid component of oxLDL with pro-atherogenic activity,
is recognized by human NKT cells (Fox et al., 2009), but presumably
not by mouse NKT cells (Brennan et al., 2011). Structure comparison
analysis with existing NKT cell ligands led to the presumption that in
addition to lysophosphatidylcholine, palmitoyl oleoyl phosphatidylcho-
line (POPC), palmitoyl linoleoyl phosphatidylcholine (PLPC), palmitoyl
arachidonoyl phosphatidylcholine (PAPC), saturated dipalmitoylpho-
sphatidylcholine (DPPC) and palmitoyl docosahexaenoyl phosphatidyl-
choline (PDPC) could be able to stimulate iNKT cells. Unpublished data
from our group now shows that oxidized 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphoryl-choline (oxPAPC), present in oxLDL, has the
capacity to stimulate NKT cells (Puijvelde et al., submitted for
publication).
6. Relation between lipoprotein metabolism and NKT cells
Loading of (endogenous) (glyco)lipid-antigens, which are mostly
present in cell-membranes, on CD1d is a complex process still under
investigation. CD1d is synthesized in the endoplasmic reticulum (ER)
and loading of lipid ligands occurs in the endosomes and lysosomes.
Several proteins that are involved in lipoprotein metabolism and linked
to atherosclerosis are also involved in the homeostasis and lipid-driven
activation of NKT cells. Microsomal triglyceride transfer protein
(MTP), a lipid transfer protein involved in the assembly of VLDL and
chylomicrons by loading lipids onto apolipoprotein B, also regulates
loading of glycolipid antigens onto CD1d and the subsequent presenta-
tion of the loaded-CD1d molecules on the surface of APCs (Brozovic
et al., 2004; Dougan et al., 2005). MTP inhibitors attenuate athero-
sclerosis (Hewing et al., 2013; Mera et al., 2015) due to a reversal of
hyperlipidaemia but the reduction in lesion size might also be caused
by a reduced loading of lipids on CD1d and subsequently in inhibited
activation of pro-atherogenic NKT cells. Elevated levels of GM2
activator protein, a sphingolipid activator protein (SAP), are found in
serum and atherosclerotic lesions of mice and humans (Yanai et al.,
2006). This lysosomal protein activates lipid-degrading enzymes and
increases the enzymes’ accessibility to lipids in the lysosomes and
endosomes. Consequently, SAPs can promote the loading of lipids on
CD1d which could explain (Zhou et al., 2004a), at least partly, how
these proteins contribute to atherosclerosis.
6.1. ApoE-LDLr pathway
A very important lipid transfer pathway involving lipoproteins and
linked to atherosclerosis in both mice and humans is the ApoE-LDLr
pathway. ApoE is involved in the clearance of lipids, especially
chylomicrons, VLDL and IDL particles from the circulation via the
interaction with the LDLr or LDLr-related protein (LRP). LRP, highly
expressed on macrophages and involved in intracellular signalling and
endocytosis, can modulate the activation of NKT cells, but is only
necessary for the IL-4 and not the IFN-γ production (Covarrubias et al.,
2014). Van den Elzen et al. revealed an important role for both apoE
and the LDLr in the CD1d-mediated presentation of exogenous NKT
cell antigens. ApoE is necessary for the effective delivery of these
antigens to the lysosomes where they can be loaded onto CD1d and
lead to iNKT cell activation. This process is receptor-mediated in which
the LDLr is an important factor (Elzen et al., 2005). Although both
apoE and the LDLr are not essential for NKT cell activation, a
deficiency in one of them leads to a dramatic decrease in NKT cell
activation. NKT cell activation by B cells is however completely LDLr-
dependent and apoE dramatically enhances B cell presentation of α-
GalCer (Allan et al., 2009). As a consequence there are major
differences in the α-GalCer-sensitivity under apoE-/- and LDLr-/-
conditions. NKT cells in apoE-/- conditions proliferate less upon
stimulation with α-GalCer (both in vitro and in vivo) suggesting that
apoE might be more important than the LDLr in lipid-loading of CD1d.
In addition, the increase in splenic and hepatic NKT cell numbers upon
high fat diet feeding was much lower in apoE-/- mice than in LDLr-/-
mice. ApoE might therefor not only be important in transport of
exogenously administered ligands but also in the transport of athero-
sclerosis-related endogenous NKT cell ligands (van Puijvelde et al.,
2009). In accordance, Braun et al. showed an impaired response to α-
GalCer in apoE-/- splenocytes compared with WT splenocytes. As
mentioned, another explanation for this can be the anergic state of
iNKT cells during hyperlipidaemia caused by a chronic activation by
endogenous ligands (Braun et al., 2010). Based upon this knowledge
we should however conclude that the mice-models (apoE-/- and LDLr-/-
mice) used in all studies on atherosclerosis are not ideal to examine the
contribution of NKT cells. To circumvent the problems with CD1d-
loading due to the deficiency in apoE or LDLr, exogenous ligands could
be loaded on wildtype (C57Bl/6) DCs followed by intravenous injec-
tion, a method shown to be even more effective in the activation of NKT
cells than direct injection of α-GalCer (Chang et al., 2005; Nagaraj
et al., 2006). As mentioned, treatment of LDLr-/- mice with OCH-
pulsed DCs strongly reduced the development of atherosclerotic lesions
(Puijvelde et al., submitted for publication). Another effective approach
could be the incorporation of lipid-ligands in liposomes (Nakamura
et al., 2015), shown to induce strong NKT cell responses and improved
antitumor effects (Nakamura et al., 2013). However, in studies with
hyperlipidemic mice, you still have to deal with the possible anergic
state of the NKT cells. Soh et al. very recently showed that this anergic
state of NKT cells with reduced capacity to produce IFN-γ, leads to an
accumulation of pro-atherogenic marginal zone B cells (Soh et al.,
2016).
7. NKT cells in other cardiovascular diseases and patients
Since NKT cells are involved in the disease process of athero-
sclerosis, the question was raised whether the prevalence or behaviour
of circulating NKT cells is also altered in patients with cardiovascular
diseases. In Table 1 and below, we briefly discuss the current knowl-
edge on the prevalence and the role of NKT cells in several cardiovas-
cular diseases and events.
7.1. Coronary artery disease
Similar to the reduction of NKT cell numbers in spleen and liver of
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mice upon the induction of atherosclerosis (Major et al., 2004; Nakai
et al., 2004), and similar to the reduced numbers observed in many
autoimmune diseases (Kis et al., 2007; van der Vliet et al., 2001;
Yanagihara et al., 1999), patients with angina pectoris (Andoh et al.,
2006) and symptomatic cardiovascular patients, patients who experi-
enced cardiovascular events in the past (Kyriakakis et al., 2010), show
lower circulating levels of NKT cells. Advanced vascularized athero-
sclerotic plaques from the symptomatic patients showed increased
numbers of CD1d-expressing cells when compared with early plaque
stages or with plaques of asymptomatic patients. This again suggests an
active migration of NKT cells from the periphery to atherosclerotic
lesions. Furthermore, the iNKT cells from these plaques co-localize
with CD1d-expressing cells, are highly reactive to α-GalCer and
promote angiogenesis and further neovascularization by producing
IL-8 (Kyriakakis et al., 2010). Although a correlation between circulat-
ing NKT cell numbers and coronary risk factors could not be
established, the prevalence of NKT cells might be a good biomarker
for atherosclerotic coronary artery disease (Andoh et al., 2006). A
recent paper by Rombouts et al. now showed a very strong correlation
between circulating NKT cell levels and intraplaque T and NKT cells,
confirming the potential of circulating NKT cells as a biomarker for
inflammatory atherosclerotic lesions (Rombouts et al., 2016).
However, more extended studies with bigger groups of patients should
be performed to confirm this. On the contrary, CD8+CD56+ NKT and
NKT-like cells producing pro-atherogenic IFN-γ persistently accumu-
late in blood from patients with coronary artery disease (acute coronary
syndrome and stable angina) (Bergström et al., 2012) and low levels of
IFN-γ expressing CD3+CD4+CD56+ NKT and NKT-like cells were
linked to an increased incidence of coronary events which may be
lipoprotein-dependent (Björkbacka et al., 2016).
7.2. Ischemia/Reperfusion injury
NKT cells are also associated with tissue injury after ischemia
reperfusion (I/R), a disease process linked to atherosclerosis. IFN-γ-
producing CD1d-restricted NKT cells are rapidly recruited to the
kidney and liver after ischemia/reperfusion induction in mice models
(Caldwell et al., 2005; Shimamura et al., 2005; Tsutahara et al., 2012).
The recruitment of CD8+ NKT cells to the injured kidney is a CXCR3
and CCR5 dependent process (Tsutahara et al., 2012). The injury is
initiated by CD1d-dependent activation of the NKT cells and can be
inhibited by the activation of the hypoxia/HIF-2α/adenosine A2A
receptor axis of iNKT cells, leading to a reduced IFN-γ production,
neutrophil influx and tissue necrosis (Lappas et al., 2006; Zhang et al.,
2016). The NKT cells also contribute directly to the liver and renal
injury by their cytotoxic, perforin and Fas/FasL-dependent function
(Shimamura et al., 2005).
Mice in which NKT cells were depleted using an anti-CD1d mAb,
blocking the interaction between APCs and NKT cells, and mice
deficient in type I NKT cells (Jα18-/- mice) showed reduced hepatic
and renal I/R injury (Arrenberg et al., 2011; Kuboki et al., 2009; Li
et al., 2007). A reduced IFN-γ production and a reduced neutrophil
accumulation were responsible for the protection against renal injury
in these mice (Li et al., 2007). Additionally, α-GalCer mediated
activation of NKT cells intensifies renal I/R injury in which both the
IL-12/IFN-γ and the IL-23/IL-17 signal pathways are involved (Li
et al., 2010). However, interestingly and surprisingly, treatment of
mice with α-GalCer resulted in an IL-13 and adenosine A2A receptor-
dependent reduction in hepatic I/R injury (Cao et al., 2009).
In contrast with the pathogenic role of type I NKT cells in I/R
injury, sulfatide-reactive type II NKT cells are now linked to a IL-10
and HIF-1α dependent protective role in liver and kidney injury after I/
R (Arrenberg et al., 2011; Yang et al., 2011). In addition, Zhang et al.
showed that treatment with rapamycin, an immunosuppressing drug
used in preventing the rejection of kidney transplants, protects the
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kine-dependent recruitment of renoprotective NKT cells. Further
research should however prove whether these NKT cells are indeed
the same type II NKT cells (Zhang et al., 2014).
Wong et al. showed that NKT cells also play a role in ischemic
reperfusion injury of the brain (stroke) and especially in the associated
systemic bacterial infection. Stroke induces a restricted crawling and
increased arrest of hepatic iNKT cells in mice which might cause the
attenuated antimicrobial responses as observed in patients.
Surprisingly, these effects were not dependent on a CD1d ligand but
were caused by a noradrenergic neurotransmitter (Wong et al., 2011).
7.3. Myocardial infarction
In line with the other studies (Andoh et al., 2006; Kyriakakis et al.,
2010) patients with acute myocardial infarction (MI) show reduced
numbers of circulating NKT cells when compared with healthy
controls. This again might be a result of an increased migration of
peripheral NKT cells to the site of inflammation, the infarcted heart
(Liu et al., 2011; Novak et al., 2015), where they peak seven days after
MI induction (Yan et al., 2013). During MI there is however no change
in the proportion of subpopulations of iNKT cells, but there is a change
in the expression of NK cell receptors leading to more pathogenic NKT
cells promoting inflammation. CD244, linked to both the activation and
the inhibition of NK cells, is downregulated while CD16, playing a role
in NK cell activation, is upregulated (Novak et al., 2015). A correlation
analysis by Liu et al. now showed that the number of iNKT cells might
be a predictor of restenosis after primary coronary stenting in acute MI
patients (Liu et al., 2011). Homma et al. and Sobirin et al. showed that
α-GalCer-induced activation of NKT cells in mice results in a con-
comitant increase in cardiac NKT cell numbers. Accompanied by a
reduction in the inflammatory status and apoptosis this leads to a
reduction in myocardial I/R injury and an amelioration of left ventricle
remodelling which were both IL-10 dependent and concomitantly
resulted in an improved survival (Homma et al., 2013; Sobirin et al.,
2012). Further investigation on the applicability of a α-GalCer based
therapy to protect the heart from I/R injury is needed since enhanced
NKT cell infiltration in the ischemic heart and particularly in the left
ventricle after I/R (Homma et al., 2013; Sobirin et al., 2012; Yan et al.,
2013) and a reduction in infarct size in iNKT cell deficient mice are
observed (Homma et al., 2013).
7.4. Aortic aneurysms
NKT cells are also found in vascular tissue affected by another
common vascular disorder, the abdominal aortic aneurysm (AAA).
AAA, a local permanent dilation of the abdominal part of the aorta, is
linked to aging and atherosclerosis. AAA is a chronic inflammatory
disease in which inflammatory cells contribute to an increased produc-
tion of elastase and several proteinases (matrix metalloproteinases
(MMPs), serine proteinases, cathepsins) which are responsible for the
structural loss of vessel wall integrity. TCRαB+CD161+ NKT cells are
one of the inflammatory cells that can be found abundantly in the
aneurysmal vessel wall. NKT cells present in AAA tissue may be
activated via a CD40/CD40L interaction with vSMCs. Upon activation,
the NKT cells predominantly produce pro-inflammatory IFN-γ which
may lead to an upregulated expression of Fas and increased FasL-
mediated apoptosis of vascular smooth muscle cells (vSMCs) leading to
atherosclerotic plaque instability and rupture (Chan et al., 2005a).
Anti-inflammatory IL-4, produced by the same NKT cells, might be
responsible for increased expression of MMPs by SMCs and macro-
phages, contributing to the development of AAA (Chan et al., 2005b).
Data from our group now establishes that mice lacking CD1d-depen-
dent NKT cells demonstrate reduced AAA severity in the angiotensin-
II-mediated AAA model in LDLr-/- mice. In addition, we show that type
I NKT cells can contribute, in a cytokine dependent way, to AAA
development by increasing the expression of matrix degrading enzymes
by macrophages and vSMCs, and by decreasing vSMC viability
(Puijvelde et al., submitted for publication).
8. Concluding remarks
Although the LDLr-/- and apoE-/- mouse models used are far from
ideal, it is generally accepted that iNKT cells are pro-atherogenic and
may affect the initiation (size) as well as the progression of athero-
sclerotic lesion development (stability). Initial studies in mice on the
role of NKT cells in atherosclerosis mainly focused on the cytokines
(IFN-γ, IL-4 and IL-10) produced upon activation, while more recent
papers now emphasize the importance of the cytotoxic capabilities of
NKT cells. Granzyme B and perforin, released by NKT cells may
contribute to the necrotic core formation, resulting in rupture-prone
instable lesions. The role of NKT cells in humans with cardiovascular
diseases remains however less clear. Overall, most cardiovascular
patients show a reduction in circulating NKT cells and a concomitant
increase in NKT cells in the affected organ. From a study by Rombouts
et al. we now learned that circulating NKT cells strongly correlate with
(NK)T cells inside the lesion, and thus might be a biomarker for the
presence of highly inflammatory lesions in both mice and humans
(Rombouts et al., 2016). The recruited NKT cells are often linked to a
progression of the disease (I/R injury, aneurysm formation, athero-
sclerosis, coronary artery disease) but might also be protective,
especially when activated by α-GalCer. Further investigation is neces-
sary to define the best strategy, most likely a dampening (DPPE-PEG,
anti-CD1d) or a modulation (structural variants of α-GalCer with
beneficial anti-inflammatory effects) of the NKT cell responses, as a
potential novel therapy against cardiovascular diseases. Extra compli-
cating is however that the NKT cell activity is highly appreciated in
cancer because of the anti-tumor activity. Therefore, the discovery of
the so far unknown endogenous ligand for NKT cells during cardio-
vascular diseases might have great impact on possible therapies.
Extensive research on these endogenous ligand (s) led to some
interesting candidates, but whether these ligands (iGb3, GD3, α-
glycosylceramides) indeed activate NKT cells during cardiovascular
diseases remains elusive.
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